Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus for Autoimmune Disease of Blood Cells

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 12 months and \< 30 years at the time of study entry~* Diagnosis of autoimmune cytopenias requiring treatment with medications~* At least one of the following: Autoimmune Neutropenia, Autoimmune Hemolytic Anemia, and/or Autoimmune Thrombocytopenia~* Must be proven autoimmune by either a documented autoantibody (positive direct anti globulin test, positive anti-neutrophil, and/or anti-platelet antibody) and/or a documented clinical response to immunosuppression~* Autoimmune Cytopenias can be idiopathic (Idiopathic Thrombocytopenic Purpura (ITP), Autoimmune Hemolytic Anemia (AIHA), Autoimmune Neutropenia (AIN), or Evans syndrome) or secondary to one of following conditions: Lupus, Rheumatoid Arthritis (RA), ALPS (Autoimmune Lymphoproliferative Syndrome), or Inflammatory bowel disease (IBD)~* Patients must have chronic disease diagnosed by either a documented cytopenia syndrome (Lupus, ALPS, RA, or IBD), or by having Evans syndrome defined as idiopathic destruction of multiple blood cell types, and/or by having disease \>6 months~* Patients must be refractory to or unable to tolerate standard front-line therapies for autoimmune cytopenias (corticosteroids and/or IVIG)~* Patients may be taking second-line agents for autoimmune cytopenias (mycophenolate mofetil, cyclosporine, tacrolimus, mercaptopurine, and/or methotrexate) at time of study entry; however, attempts should be made to wean these agents. Patients may not stay on a combination of sirolimus and a calcineurin inhibitor for greater than 4 weeks~* Informed consent/assent must be obtained prior to initiating treatment~* Patient must be able to consume oral medication in the form of tablets or solution~Exclusion Criteria:~* Pregnancy or breast feeding~* Uncontrolled infection~* Known allergy to Sirolimus or its components~* Patients with a documented malignancy on therapy or not in remission~* Patients who do not meet organ function requirements listed in protocol~* Patients with a documented history of severe combined immunodeficiency or human immunodeficiency virus infection (HIV)

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Sirolimus treatment (Type: EXPERIMENTAL): Sirolimus treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).